SOMATOM CT高压熔断丝炸裂故障分析

简要介绍西门子SOMATOM CT高压发生器的工作原理,并着重分析了高压63A熔断丝炸裂故障原因及其判断与排除方法。文章指出了在检修高压发生器的过程中特别要注意的事项。     

E1 Tor Vibio Cholerae Strain SM_6 and Jiangsu 1d Strain

Ｅ１ＴｏｒＶｉｂｉｏＣｈｏｌｅｒａｅＳｔｒａｉｎＳＭ_６ａｎｄＪｉａｎｇｓｕ１ｄＳｔｒａｉｎ￥ＪｉａｎｇＸｉａｏｗａｎ，ｅｔａｌ．ＡＣＴＡＡＣＡＤＥＭＩＡＥＭＥＤＩＣＩＮＡＥＮＡＮＪＩＮＧ，１９９４，１４（２）：１６３－１６４ＡｂｓｔｒａｃｔＥ１Ｔｏ?..     

99mTc-Annexin V检测早期凋亡多巴胺能神经元的实验研究

目的 研究放射性核素标记的膜联蛋白V(Annexin V)与凋亡的多巴胺能神经元的结合特性,探讨使用凋亡显像剂99mTc-Annexin V早期活体显像诊断帕金森病的可行性.方法 采用不同浓度的1-甲基-4-苯基吡啶离子(1-methyl-4-phenylpyridinium, MPP+)处理大鼠肾上腺嗜铬细胞瘤细胞(PC12)和人神经母细胞瘤细胞(SH-SY5Y)以诱导其凋亡(PC12 0～200 μm/L, SH-SY5Y 0～500 μm/L),FITC -Annexin V及碘化吡啶(propidiumiodide, PI)双染进行流式细胞仪凋亡检测.以99mTc-Annexin V与凋亡的细胞进行饱和结合实验及细胞摄取实验,研究凋亡细胞与Annexin V的亲和力及其摄取99mTc-Annexin V的动力学.结果 MPP+可诱导PC12细胞及SH-SY5Y细胞发生凋亡,并有明显的量效关系.凋亡细胞可特异性与99mTc-Annexin V结合,亲和力可达(7.16±1.78)nmol/L,每个凋亡的多巴胺能神经元表面的结合位点可达到(179±33)fmol/106cells (PC12)及(220±26)fmol/106cells (SH-SY5Y),且神经元的凋亡水平与其膜结合的99mTc-Annexin V放射性强度有相关性(P＜0.001).结论 凋亡的多巴胺能神经元与99mTc-Annexin V有高度亲和力,其所结合的99mTc-Annexin V放射性强度与细胞的凋亡水平相关,99mTc-Annexin V可用于检测多巴胺能神经元的早期凋亡.     

短发卡RNA对人胃癌细胞STAT3基因的沉默作用

目的:探讨STAT3基因小发夹RNA（shRNA）表达质粒对胃癌MKN-45细胞STAT3基因的干扰作用。方法:根据STAT3 mRNA 编码序列，设计RNA干扰靶点，构建STAT3基因的特异性小RNA干扰质粒（psiRNA-H1/STAT3），使用脂质体转染人胃癌细胞系（MKN-45细胞）。实验分为对照（A）组，psiRNA-H1转染（B）组和psiRNA-H1/STAT3转染（C）组。通过RT-PCR和Western Blot检测STAT3特异性小RNA干扰基因对胃癌细胞STAT3基因mRNA和蛋白表达的影响。结果:psiRNA-H1/STAT3经限制性酶切及部分序列分析证明基因插入正确，并经测序证实。将其成功转染MKN-45细胞后，该细胞的STAT3 mRNA和蛋白表达均明显下降(P<0.05)。 结论:将成功构建的针对STAT3基因的shRNA表达载体转染MKN-45细胞，能有效抑制该细胞的STAT3 mRNA和蛋白表达，为STAT3基因靶向治疗提供一定的实验依据。     

99Tcm-HYNIC-Annexin V动脉粥样硬化显像的实验研究

目的 探讨99Tcm-联肼尼克酰胺(HYNIC)-膜联蛋白V(Annexin V)显像检测兔动脉粥样硬化(AS)病变的价值.方法 5只雄性日本大耳白兔通过免疫损伤血管和12周高脂饮食制备成AS模型(实验组),自兔耳缘静脉按体质量注射99Tcm-HYNIC-Annexin V 37 MBq/kg,分别行活体和离体血管的99Tcm-HYNIC-Annexin V显像.5只未经特殊处理的同种白兔行活体显像作为对照.对实验组兔的主动脉分段后,测定各片段质量和放射性计数,并进行病理学和免疫组织化学检查.采用SPSS 13.0软件对数据进行统计学处理.结果 显像剂注射后2h,实验组兔主动脉可见放射性摄取达峰值,而对照组未见明显的放射性摄取,前者靶/非靶(T/NT)比值(2.70±0.26)明显高于后者(1.30±0.13,t=1.99,P＜0.05).实验组兔的主动脉血管斑块片段放射性摄取(每克组织百分注射剂量率,%ID/g)为(0.075±0.016)%ID/g,明显高于非斑块血管片段[(0.035±0.013)%ID/g,前者是后者的(4.55±0.99)倍,t=4.77,P＜0.001];两者的凋亡细胞指数(AI)分别为(40.53±14.94)%和(11.90±7.09)%,差异具有统计学意义(t=2.54,P＜0.01).所有血管片段的放射性摄取(%ID/g值)与AI呈正相关(r=0.98,P＜0.001).结论 99Tcm-HYNIC-Annexin V可以无创性地检测AS斑块的凋亡.     

Synthesis of [3H] vardenafil,Levitra®, using a new labeling technique

Tritium was introduced into the new orally active, selective phosphodiesterase type V (PDE V) inhibitor vardenafil (Levitra^®), by reduction of a suitable amide precursor with freshly prepared lithium aluminum tritide. A specific activity of 52.7 Ci/mmol (1.95 TBq/mmol) was achieved. In order to overcome the usual technical difficulties during the preparation of complex tritides a new and easy labeling technique which has considerable potential for various tritia‐tion procedures, was developed. Copyright © 2003 John Wiley & Sons, Ltd.     

HELLP syndrome associated with factor V R506Q mutation

The pathogenesis of HELLP (haemolysis, elevated liver enzyme and low platelet count) syndrome, a severe presentation of pre-eclampsia, is still an enigma. Activated protein C resistance resulting from a mutation in coagulation factor V has recently emerged as the leading cause of thrombosis in pregnancy. We report on two patients with HELLP syndrome who were found to be heterozygous for factor V R506Q mutation, leading to activated protein C resistance. These findings suggest that the pathogenesis of HELLP syndrome is associated with a thrombotic process, and point to the potential benefit of anti-thrombotic therapy in this condition.     

Prospective Randomized Study Comparing the Efficacy of Bioequivalent Doses of glycosylated and nonglycosylated rG-CSF for Mobilizing Peripheral Blood Progenitor Cells

Thirty patients diagnosed with breast cancer were included in a prospective randomized study comparing the in vivo priming effect of bioequivalent doses of glycosylated (lenograstim) and nonglycosylated (filgrastim) rG-CSF administration. Analysis of the efficacy of equivalent biological doses of both rG-CSFs showed no significant differences either in the mobilization of the subpopulations of PBPC considered (CD34⁺, CD34⁺/38⁻, CD34⁺/DR⁻), the content of such CD34⁺ cell subsets in the leukapheresis product, or the cost of the mobilization and collection procedures between both recombinant molecules. These results suggest that priming with bioequivalent doses of the two commercially available forms of glycosylated or nonglycosylated rG-CSF has a similar in vivo effect on PBPC mobilization.